MAP Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Allergan, Inc.

Wed Jan 23, 2013 11:45am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130123:nPnNY47075


NEW YORK,  Jan. 23, 2013  /PRNewswire/ -- Bernstein Liebhard LLP  is
investigating whether the Board of Directors of MAP Pharmaceuticals, Inc. ("MAP
Pharmaceuticals" or the "Company") (NASDAQ: MAPP) breached its fiduciary duty to
its shareholders in agreeing to sell MAP Pharmaceuticals to Allergan, Inc.
(NYSE: AGN).

(Logo:  http://photos.prnewswire.com/prnh/20120202/MM47134LOGO)

Under the terms of the agreement, MAP Pharmaceuticals shareholders will receive 
$25.00  in cash for each share they own.  The investigation is focused on the
potential unfairness of the price to MAP Pharmaceuticals shareholders and the
process by which the MAP Pharmaceuticals Board of Directors considered and
approved the transaction.

If you are interested in discussing your rights as a MAP Pharmaceuticals
stockholder, with no obligation or cost to you, please contact  U. Seth
Ottensoser  at:  

(877) 779-1414
or
Ottensoser@bernlieb.com.

Bernstein Liebhard LLP  has pursued hundreds of securities,  consumer  and
shareholder rights cases and recovered over  $3 billion  for its clients.  It
has been named to  The National Law Journal's  "Plaintiffs' Hot List" in each of
the last ten years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York  10016
(877) 779-1414
www.bernlieb.com

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP.  The law firm responsible
for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street,  New
York, New York  10016, (212) 779-1414.  The lawyer responsible for this
advertisement in the  State of Connecticut  is Michael S. Bigin.  Prior results
do not guarantee or predict a similar outcome with respect to any future matter.

SOURCE  Bernstein Liebhard LLP

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.